Ocugen (OCGN) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
SAB Biotherapeutics (SABS) has outperformed Ocugen (OCGN) over the past year, losing 28.9% versus a loss of 33.8%. Over five years, OCGN leads with a -88.1% price change compared with -97.3% for SABS. Ocugen is the larger company by market cap ($260.6 million vs $253.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCGN | SABS |
|---|---|---|
| Share price | $0.7679 | $2.81 |
| Market cap | $260.55M | $253.15M |
| 1-day change | +4.79% | -3.44% |
| YTD return | -43.12% | -24.87% |
| 1-year return | -33.80% | -28.86% |
| 5-year return | -88.09% | -97.32% |
| EPS (TTM) | $-0.20 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.41M | $0 |
| Revenue growth (YoY) | +8.83% | -100.00% |
| Net income (latest FY) | $-67.85M | $13.27M |
| Operating margin | -1425.70% | — |
| Net margin | -1537.41% | — |
| 52-week high | $2.73 | $5.15 |
| 52-week low | $0.691 | $2.44 |
| Distance from 52-week high | -71.82% | -45.44% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1484.84% | +314.23% |
| Average volume | 7.34M | 633.60K |
| Shares outstanding | 339.31M | 90.09M |
| Employees | 116 | 86 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Ocugen grew revenue faster in its latest fiscal year (+8.83% vs -100.00%).
About Ocugen
OCGN stock →Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees
OCGN vs SABS FAQ
Which is bigger, Ocugen or SAB Biotherapeutics?
Ocugen (OCGN) is larger, with a market capitalization of $260.55M compared with $253.15M for SAB Biotherapeutics (SABS).
Which stock has performed better over the past year, OCGN or SABS?
SABS returned -28.86% over the past 12 months, compared with -33.80% for OCGN (price return, excluding dividends). Past performance does not predict future results.
Are Ocugen and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.